Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
---|---|
Information provided by: | Boehringer Ingelheim Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00620516 |
This is a descriptive observational open non-comparative study of the safety and efficacy of tiotropium inhalation capsule given at 18mcg once a day for 30 days among Korean patients with COPD. At Visit 1, patients who are diagnosed as COPD will be prescribed tiotropium inhalation capsule at 18mcg once daily (at the same time). Patients' FEV1 will be assessed before start of treatment (Visit 1) and at the end of the 30 day treatment period (Visit 2). Occurrence of adverse events will also be asked from the patient at the end of the 30 day treatment period. Patients will be informed by the attending physicians to immediately report the occurrence of serious adverse events.
Condition |
---|
Pulmonary Disease, Chronic Obstructive |
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | Tiotropium 18ug Inhalation Capsule Using a Handihaler® Among Korean COPD Patients: A 30 Day, Open-Label, Post-marketing Study |
Estimated Enrollment: | 3000 |
Study Start Date: | July 2005 |
Estimated Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
Study Design:
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
3227
Inclusion Criteria:
Older than 40 years old Diagnosed as COPD No Previous Spiriva administration No Contraindication for Spiriva according to the product label
Exclusion Criteria:
patients with history of hypersensitivity to atropine and its derivatives (e.g. ipratropium oxitropium or any component of this product).
Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals |
Responsible Party: | Boehringer Ingelheim ( Boehringer Ingelheim, Study Chair ) |
Study ID Numbers: | 205.337 |
Study First Received: | February 4, 2008 |
Last Updated: | August 26, 2009 |
ClinicalTrials.gov Identifier: | NCT00620516 History of Changes |
Health Authority: | Korea, Republic of: Korea Food and Drug Administration |
Neurotransmitter Agents Lung Diseases, Obstructive Cholinergic Antagonists Respiratory Tract Diseases Lung Diseases Anti-Asthmatic Agents |
Chronic Disease Peripheral Nervous System Agents Cholinergic Agents Tiotropium Bronchodilator Agents Pulmonary Disease, Chronic Obstructive |
Respiratory System Agents Parasympatholytics Neurotransmitter Agents Disease Attributes Molecular Mechanisms of Pharmacological Action Cholinergic Antagonists Physiological Effects of Drugs Anti-Asthmatic Agents Cholinergic Agents Pharmacologic Actions Lung Diseases, Obstructive |
Pathologic Processes Respiratory Tract Diseases Autonomic Agents Therapeutic Uses Lung Diseases Chronic Disease Peripheral Nervous System Agents Tiotropium Bronchodilator Agents Pulmonary Disease, Chronic Obstructive |